Becton, Dickinson and Company (LON:0R19)

Revenue Breakdown

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Medication Delivery Solutions Revenue	4.58B
Medication Management Solutions Revenue	3.47B
Pharmaceutical Systems Revenue	2.32B
Advanced Patient Monitoring Revenue	1.08B
Specimen Management Revenue	1.87B
Diagnostic Solusions Revenue	1.84B
Integrated Diagnostic Solutions Revenue	3.71B
Biosciences Revenue	1.46B
Surgery Revenue	1.57B
Peripheral Intervention Revenue	2.00B
Urology and Critical Care Revenue	1.65B
Revenue (Other)	-3.71B
Revenue (Total)	21.84B

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
United States Revenue	12.79B
International Revenue	9.05B
Revenue (Other)	1.00M
Revenue (Total)	21.84B

Revenue Breakdown 2

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Medical Revenue	11.46B
Life Sciences Revenue	5.17B
Interventional Revenue	5.22B
Revenue (Total)	21.84B

EBIT

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Medical Segment Operating Income	4.14B
Life Sciences Segment Operating Income	1.64B
Interventional Segment Operating Income	2.25B
Operating Income (Total)	2.58B

Updated Sep 30, 2025. Data Source: Fiscal.ai.